Cocrystal Pharma Stock Quote COCP - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

2.20

Bid

2.15

Ask

3.45

Volume

9,435

2.19 Day's Range 2.22

1.325 52 Week Range 3.285

Market Cap

22.382M

Previous Close

2.22

Open

2.21

Last Trade

2.28

Last Trade Time

Financial Volume

$ 20,789

VWAP

2.2033

Average Volume (3m)

36,291

Shares Outstanding

10,173,790

Dividend Yield

PE Ratio

-1.24

Earnings Per Share (EPS)

-1.77

Revenue

2.6M

Net Profit

-17.98M

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first... Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.cocrystalpharma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Cocrystal Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker COCP. The last closing price for Cocrystal Pharma was $2.22. Over the last year, Cocrystal Pharma shares have traded in a share price range of $ 1.325 to $ 3.285.

Cocrystal Pharma currently has 10,173,790 shares outstanding. The market capitalization of Cocrystal Pharma is $22.59 million. Cocrystal Pharma has a price to earnings ratio (PE ratio) of -1.24.

Form 8-K - Current report

Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the...

Form 8-K - Current report

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed...

Form DEF 14A - Other definitive proxy statements

Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with...

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.15	-6.3829787234	2.35	2.4479	2.19	19672	2.29890364	CS
4	-0.09	-3.93013100437	2.29	2.6	2.1	29497	2.29903125	CS
12	0.63	40.127388535	1.57	3.1	1.53	36291	2.28418253	CS
26	0.63	40.127388535	1.57	3.1	1.325	23792	2.04101848	CS
52	-0.45	-16.9811320755	2.65	3.285	1.325	24242	2.12170073	CS
156	-11.36	-83.7758112094	13.56	17.88	1.325	478480	11.66430661	CS
260	-23.6	-91.4728682171	25.8	49.2	1.325	2053740	18.84581367	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	260.07k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.61M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M